The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study

Sukowati, Caecilia; Anfuso, Beatrice; Torre, Giuliano; Francalanci, Paola; Crocè, Lory Saveria; Tiribelli, Claudio

doi:10.1371/journal.pone.0076830

Cited by 81 publications

(73 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, Chen et al' study [15] identi ed CD90 as one of marker of CAFs and demonstrated that CD90 + CAFs promoted stem-like properties in lung cancer cells. Evidences from multiple studies indicated CD90 as a candidate marker of CAFs [13][14][15]32]. Our ndings showed that most of CD90 was mainly expressed in CAFs and some endothelium, which were consistent with previous ndings in pancreatic carcinoma [32], lung cancer [15] and HCC [14].…”

Section: Discussionsupporting

confidence: 92%

“…Instead, they reported CD90 as a maker of satellite cells/myo broblasts subpopulation [31]. Sukowati et al [13] found that CAFs isolated from human HCC tissues were positive for CD90. In addition, Chen et al' study [15] identi ed CD90 as one of marker of CAFs and demonstrated that CD90 + CAFs promoted stem-like properties in lung cancer cells.…”

Section: Discussionmentioning

confidence: 99%

“…In humans, it is mainly expressed on several types of cells including: broblasts, blood stem cells and activated microvascular endothelial cells (ECs) [9,10]. Nevertheless, high level of CD90 expression has also been observed in CAFs [11][12][13]. Sukowati et al [14] found that CAFs isolated from human HCC tissues were positive for CD90.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection

Zhao¹,

Zhou²,

Chen³

et al. 2015

neo

View full text Add to dashboard Cite

CD90 has been identi ed as a candidate marker of cancer stem cells (CSCs) for HCC, whereas it also has been considered as a marker for tumor-associated broblasts (CAFs). OCT4, as a key transcription factor required to maintain pluripotency of human embryonic stem cell and cancer cells, has been characterized to be involved in malignant transformation and tumorigenesis of various cancers. is study aimed to examine expression patterns of CD90 in HCC and investigate whether combination of both CD90 and OCT4 could provide a more powerful predictor for prognosis of HCC than either one alone.CD90 and OCT4 were examined by immunohistochemistry. e relationship between CD90/OCT4 expression and clinicopathologic characteristics was analyzed. e correlation between CD90/OCT4 expression and overall survival and disease-free survival was determined with Kaplan-Meier analysis.CD90 was found mainly expressed in tumor-associated CAFs and OCT4 was mainly expressed in tumor cells. e expression of CD90 and OCT4 in HCC was signi cantly higher than in adjacent non-tumor and normal liver tissues. CD90 expression was correlated with pathological grade, satellite lesion, PVTT and recurrence. OCT4 expression was correlated with pathological grade, tumor size and recurrence. Data demonstrated no correlation between CD90 and OCT4. High expression of CD90 or OCT4 predicts a poor prognosis. Furthermore, combination of both CD90 and OCT4 provides a more sensitive predictor for prognosis of HCC than either marker alone.CD90 and OCT4 are both independent and reliable biomarker for predicting prognosis of HCC patients a er hepatic resection. Our results indicated the accuracy of prediction can be enhanced by their combination.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection

Zhao¹,

Zhou²,

Chen³

et al. 2015

neo

View full text Add to dashboard Cite

show abstract

“…A number of transcripts that encode proteins involved in cell-cell interactions (SI Appendix, Table S4) were up-regulated, including the gap junction proteins GJC1 and GJA5 and the integrins alpha-7 (ITGA7) and alpha5 (ITGAV). Two adhesion molecules that have been shown to be increased in HCC were also increased: cadherin-13 (CDH13) (40) and Cluster of Differentiation 90 (THY1) (41). Also up-regulated are transcripts for the roundabout homolog 1 (ROBO1) and its ligand (SLIT2), as well as Jagged-1 (JAG1), which interacts with the notch receptor and whose overexpression is associated with poor prognosis in breast cancer (42).…”

Section: Resultsmentioning

confidence: 99%

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma

Simon

Freije

Farber

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

117

174

View full text Add to dashboard Cite

Fibrolamellar hepatocellular carcinoma (FLHCC) tumors all carry a deletion of ∼400 kb in chromosome 19, resulting in a fusion of the genes for the heat shock protein, DNAJ (Hsp40) homolog, subfamily B, member 1, DNAJB1, and the catalytic subunit of protein kinase A, PRKACA. The resulting chimeric transcript produces a fusion protein that retains kinase activity. No other recurrent genomic alterations have been identified. Here we characterize the molecular pathogenesis of FLHCC with transcriptome sequencing (RNA sequencing). Differential expression (tumor vs. adjacent normal tissue) was detected for more than 3,500 genes (log2 fold change ≥1, false discovery rate ≤0.01), many of which were distinct from those found in hepatocellular carcinoma. Expression of several known oncogenes, such as ErbB2 and Aurora Kinase A, was increased in tumor samples. These and other dysregulated genes may serve as potential targets for therapeutic intervention.

show abstract

“…In contrast to differentiated tumor cells, CSCs are relatively quiescent and have a slow cycling rate [20]. CSCs also have the ability to form tumors when they are injected into non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice [21][22][23][24]. Characteristically, CSCs are also radiotherapy and chemotherapy-resistant.…”

Section: Characteristics Of Cscsmentioning

confidence: 99%

Surface markers of hepatocellular cancer stem cells and their clinical potential

Feng¹,

Wang²,

Hu³

et al. 2014

neo

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with capabilities of self-renewal, differentiation, and tumorigenicity when transplanted into immune-comprised mice. Accumulating evidences have shown that CSCs or tumor-initiating cells are key drivers of tumor formation and progression in both solid tumors and haematological malignancies. Identification of the CSCs or tumor-initiating cells is a fundamental and important problem in cancer research. There is still a lack of consensus regarding the existence of a "global" marker for CSCs in different human cancers, but isolated CSCs have shown both the tumor-propagating ability in immune-compromised mice and the capacity to fully recapitulate the original heterogeneity of cell types. Several cell surface markers, including CD133, CD44 and CD90, were often used to identify and enrich CSCs. Although not all types of cancer follow the CSC theory, it provides an attractive cellular mechanism to account for the therapeutic resistance and recurrence of the disease. Here we provide a brief review regarding the markers for identification of CSCs in hepatocellular cancer, allowing us to deep understand of the cellular organization of HCC and to develop therapies that target specific CSCs.

show abstract

The Expression of CD90/Thy-1 in Hepatocellular Carcinoma: An In Vivo and In Vitro Study

Cited by 81 publications

References 34 publications

The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection

The prognostic value of combination of CD90 and OCT4 for hepatocellular carcinoma after curative resection

Transcriptomic characterization of fibrolamellar hepatocellular carcinoma

Surface markers of hepatocellular cancer stem cells and their clinical potential

Contact Info

Product

Resources

About